Dr. Pamela Miel, MD
Claim this profileThe Oncology Institute of Hope and Innovation
Studies Tumors
Studies B Cell Malignancies
5 reported clinical trials
13 drugs studied
Affiliated Hospitals
Clinical Trials Pamela Miel, MD is currently running
Disitamab Vedotin + Pembrolizumab vs Chemotherapy
for Bladder Cancer
This study will enroll participants with urothelial cancer (UC). UC can include cancer of the bladder, kidney, or the tubes that carry pee through the body (ureter, urethra). This study will try to find out if the drugs disitamab vedotin with pembrolizumab works better than platinum-containing chemotherapy to treat patients with UC. This study will also test what side effects happen when participants take these drugs together. A side effect is anything a drug does to the body besides treating the disease. Participants in this study will have cancer that has spread through the body (metastatic) or spread near where it started (locally advanced). In this study, there are 2 different groups. Participants will be assigned to a group randomly. Participants in the disitamab vedotin arm will get the study drug disitamab vedotin once every two weeks and pembrolizumab once every 6 weeks. Participants in the standard of care arm will get gemcitabine once a week for 2 weeks with either cisplatin or carboplatin once every 3 weeks.
Recruiting2 awards Phase 3
SPd vs EloPd Chemotherapy
for Multiple Myeloma
This phase 3 randomized, open-label multicenter trial will compare the efficacy, safety and the impact on health-related quality of life (HR-QoL) of SPd versus EloPd in pomalidomide-naïve patients with MM who have received 1 to 4 prior anti-MM regimens and been treated with an immunomodulatory imide drug (IMiD), proteasome inhibitor (PI) and an anti-CD38 monoclonal antibody (mAb).
Recruiting2 awards Phase 318 criteria
More about Pamela Miel, MD
Clinical Trial Related1 year of experience running clinical trials · Led 5 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Pamela Miel, MD has experience with
- Orelabrutinib (ICP-022)
- Selinexor
- Elotuzumab
- Dexamethasone Oral
- Pomalidomide
- Supra-Pharmacologic Dexamethasone Sodium Phosphate
Breakdown of trials Pamela Miel, MD has run
B Cell Malignancies
Plasma Cell Neoplasms
Multiple Myeloma
Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Pamela Miel, MD specialize in?
Pamela Miel, MD focuses on Tumors and B Cell Malignancies. In particular, much of their work with Tumors has involved Stage IV patients, or patients who are undergoing treatment.
Is Pamela Miel, MD currently recruiting for clinical trials?
Yes, Pamela Miel, MD is currently recruiting for 4 clinical trials in Whittier California. If you're interested in participating, you should apply.
Are there any treatments that Pamela Miel, MD has studied deeply?
Yes, Pamela Miel, MD has studied treatments such as Orelabrutinib (ICP-022), Selinexor, Elotuzumab.
What is the best way to schedule an appointment with Pamela Miel, MD?
Apply for one of the trials that Pamela Miel, MD is conducting.
What is the office address of Pamela Miel, MD?
The office of Pamela Miel, MD is located at: The Oncology Institute of Hope and Innovation, Whittier, California 90602 United States. This is the address for their practice at the The Oncology Institute of Hope and Innovation.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.